{"id":1985,"date":"2025-01-31T09:34:07","date_gmt":"2025-01-31T09:34:07","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?page_id=1985"},"modified":"2025-05-16T11:04:33","modified_gmt":"2025-05-16T11:04:33","slug":"technology","status":"publish","type":"page","link":"https:\/\/www.nordicbioscience.com\/technology\/","title":{"rendered":"Technology"},"content":{"rendered":"
\n
\n
\n

Technology <\/h1>\n

With precise, non-invasive biomarkers, we provide crucial insights into tissue remodeling, helping to advance clinical trials, reduce financial burdens, and improve personalized treatment strategies. Our robust immunoassays ensure high standards for accuracy, offering a deeper understanding of disease mechanisms for better drug development outcomes.<\/p>\n

\n \n Browse our biomarker portfolio \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n
\n \n
\n
\n
\n
\n

Nordic ProteinFingerPrint Technology\u2122 <\/h2>\n \n\n <\/div>\n
\n

Nordic Bioscience’s ProteinFingerPrint Technology\u2122 is backed by more than 30 years of research and used by world-leading pharmaceutical companies. Our\u00a0extracellular matrix-based approach<\/a>\u00a0quantifies disease activity with precision unmatched by omics providers, offering mechanistic and pharmacodynamic insights into tissue remodeling, a process crucial to understand when evaluating the effect of a therapeutic Intervention.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about Nordic ProteinFingerPrint Technology\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

The FIB-NIT\u2122 biomarker panel <\/h2>\n \n\n <\/div>\n
\n

FIB-NIT\u2122 (Fibrosis Non-Invasive Tests) is an innovative panel that utilizes biomarkers of fibrotic processes.<\/p>\n

These biomarkers have been proven to associate with superior pharmacodynamic and supportive prognostic performance to investigate dynamics within fibrotic diseases, including understanding drug efficacy in such indications \u2014demonstrated in over 100 publications in relevant and peer-reviewed scientific journals.<\/p>\n

The FIB-NIT\u2122 panel consists of the fibrogenesis\u00a0nordicPRO-C3\u00ae<\/a>, the fibrolysis\u00a0nordicCTX-III\u2122<\/a>, and the outcome risk\u00a0nordicPRO-C6\u2122<\/a>\u00a0biomarkers.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about the FIB-NIT\u2122 biomarker panel \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

RheumaTrace\u2122<\/h2>\n \n\n <\/div>\n
\n

The RheumaTrace\u2122 biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications.<\/p>\n

The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics. Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, and the efficacy of therapeutic interventions.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about RheumaTrace\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

CPa9-HNE, the serum calprotectin<\/h2>\n \n\n <\/div>\n
\n

Inflammatory bowel disease<\/a>, also known as IBD, is a chronic intestinal disease where neutrophils play a crucial role by producing and releasing calprotectin. Fecal calprotectin is a well-established biomarker for IBD, but low patient compliance with fecal sample collection has been a challenge.<\/p>\n

Learn more about neutrophils, NETosis, calprotectin, and how a simple blood sample can assist\u00a0patients, physicians, and clinicians to accurately quantify true neutrophil and disease activity in IBD and other chronic inflammatory diseases.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about nordicCPa9-HNE\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

NordicPRO-C3\u2122<\/h2>\n \n\n <\/div>\n
\n

NordicPRO\u2011C3\u2122 is a highly reliable and precise biomarker assay that measures active fibrosis by detecting the formation of type III collagen \u2013 a key driver of fibrogenesis across major organs, including the liver, lungs, kidneys, heart, intestines, and skin.<\/p>\n

NordicPRO-C3\u2122\u00a0provides a powerful tool for monitoring treatment efficacy and tracking disease progression over time. Furthermore, it serves as a critical decision-making tool in clinical trials, helping researchers assess treatment impact, understand the mechanism of action, and accelerate drug development.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about nordicPRO-C3\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Translational models <\/h2>\n \n\n <\/div>\n
\n

There is a need for better translational models in drug development, as the drug development process is long, complex and expensive. Therefore, it is important to increase the likelihood of success so that innovation is not weakened.<\/p>\n

The FDA and EMA have expressed the view that biomarker-based drug development strategies, in combination with translational research, may offer a biology-focused approach that reduces time and cost and increases the overall likelihood of success.<\/p>\n

 <\/p>\n <\/div>\n <\/div>\n

\n \n Read more about translational models \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

The Nordic Bioscience laboratory<\/h2>\n \n\n <\/div>\n
\n

The\u00a0Nordic Bioscience laboratory\u00a0services<\/a>\u00a0are performed in compliance with international standards for GCP and GLP. Our operations are accredited by the College of American Pathologists (CAP). We have a long history of measuring and providing clinical data used by decision-makers to make vital decisions.<\/p>\n

Our laboratory has the capacity to provide customized solutions. We have scientific biomarker experts, experienced project managers, and high-quality equipment to handle, plan and execute biomarker strategies across many levels in any organization – no project is too little, and no organization is too big.<\/p>\n <\/div>\n <\/div>\n

\n \n Read more about our laboratory services \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Get in touch<\/h2>\n \n\n <\/div>\n
\n
\n
\n Are you interested in exploring collaboration possibilities?\u2028Enter your information in the form and a representative will contact you shortly. <\/div>\n
\n +45 4452 5252<\/a>\n Contact us via email!<\/a>\n <\/div>\n <\/div>\n \n
\n

<\/p>

    <\/ul><\/div>\n
    \n
    \n<\/fieldset>\n
    \n